Analysis of somatostatin receptors and somatostatin promoter methylation in human gastric cancer

Shi,Xuefei; Li,Xiao; Chen,Lin; Wang,Chunhui

doi:10.3892/ol.2013.1614

Analysis of somatostatin receptors and somatostatin promoter methylation in human gastric cancer

Authors:
- Xuefei Shi
- Xiao Li
- Lin Chen
- Chunhui Wang
View Affiliations

Affiliations: Department of Gastroenterology, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Published online on: October 10, 2013 https://doi.org/10.3892/ol.2013.1614
Pages: 1794-1798

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Somatostatin (SST) is a gut peptide that is able to inhibit the growth of tumor cells in gastric cancer and other types of cancer. The present study investigated the mRNA and protein levels of SST and SST receptors (SSTRs) in human gastric cancer, and detected the DNA methylation of the SST promoter. The protein levels of SST were detected using a radioimmunoassay in 102 human gastric tissue specimens (51 pairs of samples from 51 gastric cancer patients, each pair of samples included a cancer tissue and a normal tissue sample). SST and SSTR mRNA expression was assessed by reverse transcription‑PCR (RT‑PCR), while SST promoter methylation was examined using quantitative methylation‑specific PCR (qMSP) in 51 pairs of tissues. The association between SST protein and RNA levels and SST methylation and gastric cancer were also analyzed. The protein levels of SST were decreased in the gastric cancer group compared with those of the normal group (5.091±0.994 vs. 7.399±0.956 pg/mg; P<0.01). The RT‑PCR analysis indicated that the mRNA levels of SST (0.218±0.183 vs. 0.456±0.331; P<0.001) and SSTRs in the gastric cancer group were lower compared with those of the normal gastric tissue group. The methylation proportion of SST was 45.1% (23/51) in the carcinoma group and 3.9% (2/51) in the normal group. In conclusion, SST promoter methylation is a common event in human gastric cancer and is connected with a decrease in SST protein and RNA levels and associated with gastric carcinogens.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Sapari NS, Loh M, Vaithilingam A and Soong R: Clinical potential of DNA methylation in gastric cancer: a meta-analysis. PLoS One. 7:e362752012. View Article : Google Scholar : PubMed/NCBI
3	González CA and Agudo A: Carcinogenesis, prevention and early detection of gastric cancer: where we are and where we should go. Int J Cancer. 130:745–753. 2012.PubMed/NCBI
4	Yamamoto E, Suzuki H, Takamaru H, Yamamoto H, Toyota M and Shinomura Y: Role of DNA methylation in the development of diffuse-type gastric cancer. Digestion. 83:241–249. 2011. View Article : Google Scholar : PubMed/NCBI
5	Yamashita K, Sakuramoto S and Watanabe M: Genomic and epigenetic profiles of gastric cancer: potential diagnostic and therapeutic applications. Surg Today. 41:24–38. 2011. View Article : Google Scholar : PubMed/NCBI
6	Wang CH, Tang CW, Liu CL and Tang LP: Inhibitory effect of octreotide on gastric cancer growth via MAPK pathway. World J Gastroenterol. 9:1904–1908. 2003.PubMed/NCBI
7	Tang C, Liu C, Zhou X and Wang C: Enhanced inhibitive effects of combination of rofecoxib and octreotide on the growth of human gastric cancer. Int J Cancer. 112:470–474. 2004. View Article : Google Scholar : PubMed/NCBI
8	Xie Y, Chen S, Wang CH and Tang CW: SOM230 combined with celecoxib prolongs the survival in nude mice with HepG-2 xenografts. Cancer Biol Ther. 12:86–92. 2011. View Article : Google Scholar : PubMed/NCBI
9	Jackson K, Soutto M, Peng D, Hu T, Marshal D and El-Rifai W: Epigenetic silencing of somatostatin in gastric cancer. Dig Dis Sci. 56:125–130. 2011. View Article : Google Scholar : PubMed/NCBI
10	Fuchs CS and Mayer RJ: Gastric carcinoma. N Engl J Med. 333:32–41. 1995. View Article : Google Scholar
11	Abbaszadegan MR, Moaven O, Sima HR, Ghafarzadegan K, A’rabi A, Forghani MN, Raziee HR, Mashhadinejad A, Jafarzadeh M, Esmaili-Shandiz E and Dadkhah E: p16 promoter hypermethylation: a useful serum marker for early detection of gastric cancer. World J Gastroenterol. 14:2055–2060. 2008. View Article : Google Scholar : PubMed/NCBI
12	Fleisher AS, Esteller M, Tamura G, Rashid A, Stine OC, Yin J, Zou TT, Abraham JM, Kong D, Nishizuka S, et al: Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. Oncogene. 20:329–335. 2001. View Article : Google Scholar
13	Homma N, Tamura G, Honda T, Matsumoto Y, Nishizuka S, Kawata S and Motoyama T: Spreading of methylation within RUNX3 CpG island in gastric cancer. Cancer Sci. 97:51–56. 2006. View Article : Google Scholar : PubMed/NCBI
14	Kang YH, Lee HS and Kim WH: Promoter methylation and silencing of PTEN in gastric carcinoma. Lab Invest. 82:285–291. 2002. View Article : Google Scholar : PubMed/NCBI
15	Zou B, Chim CS, Zeng H, Leung SY, Yang Y, Tu SP, Lin MC, Wang J, He H, Jiang SH, et al: Correlation between the single-site CpG methylation and expression silencing of the XAF1 gene in human gastric and colon cancers. Gastroenterology. 131:1835–1843. 2006. View Article : Google Scholar : PubMed/NCBI
16	Gardiner-Garden M and Frommer M: CpG Islands in vertebrate genomes. J Mol Biol. 196:261–282. 1987. View Article : Google Scholar : PubMed/NCBI
17	Bird AP: CpG-rich islands and the function of DNA methylation. Nature. 321:209–213. 1986. View Article : Google Scholar : PubMed/NCBI
18	Zhao B, Yang P, Yang J and Cai D: A randomized trial of somatostatin to regulate the VEGFs/VEGFRs in patients with gastric cancer. Hepatogastroenterology. 58:1425–1430. 2011. View Article : Google Scholar : PubMed/NCBI
19	Jin Z, Mori Y, Hamilton JP, Olaru A, Sato F, Yang J, Ito T, Kan T, Agarwal R and Meltzer SJ: Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis. Cancer. 112:43–49. 2008. View Article : Google Scholar : PubMed/NCBI
20	Mori Y, Cai K, Cheng Y, Wang S, Paun B, Hamilton JP, Jin Z, Sato F, Berki AT, Kan T, et al: A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology. 131:797–808. 2006. View Article : Google Scholar : PubMed/NCBI
21	Torrisani J, Hanoun N, Laurell H, Lopez F, Maoret JJ, Souque A, Susini C, Cordelier P and Buscail L: Identification of an upstream promoter of the human somatostatin receptor, hSSTR2, which is controlled by epigenetic modifications. Endocrinology. 149:3137–3147. 2008. View Article : Google Scholar : PubMed/NCBI
22	Liu Z, Marquez M, Nilsson S and Holmberg AR: Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells. Oncol Rep. 20:151–154. 2008.PubMed/NCBI